Login to Your Account



Other News To Note


Tuesday, June 11, 2013
• Biolinerx Ltd., of Jerusalem, said it signed an out-licensing agreement with Jiagsu chia-tai Tianqing Pharmaceutical Co. Ltd. (CCTQ), of Jiangsu, China, for the development and commercialization of BL-8030, an oral treatment for hepatitis C virus.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription